Please assess the completion status of the following clinical trial:

Trial Title: Ranibizumab in Preventing Failure of Ahmed Valve Glaucoma Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. ability to provide written informed consent and comply with study assessment for the full duration of the study.~2. age ≥ 21~3. diagnosis of glaucoma and determined to be candidate for therapy with tube insertion.~Exclusion Criteria:~1. pregnant or lactating females~2. Persons on oral contraceptives and women of child-bearing age~3. prior enrollment in the study~4. any conditions the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated~5. participation in another simultaneous medical investigation or trial~6. history of active inflammatory, infectious, or idiopathic keratitis precluding view of anterior segment structures~7. previous injections of ranibizumab in either eye.~8. Persons on Plavix (clopidogrel bisulfate) and coumadin~9. Persons with uncontrolled high blood pressure~10. Persons with renal or liver disease

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ranibizumab (Type: ACTIVE_COMPARATOR): Ranibizumab (0.5 mg in 0.05 mL) administered intravitreally at 3 time points: 9 days before Ahmed tube insertion for open-angle glaucoma, 1 month post-surgery, and 2 months post-surgery
- Usual care (Type: NO_INTERVENTION): Standard of care Ahmed tube insertion for open-angle glaucoma without injections of Ranibizumab

Based on this trial design, predict the completion outcome and termination type (if applicable).